Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
108021295 | 10802129 | 5 | F | 20140716 | 20160725 | 20150217 | 20160729 | EXP | JP-JNJFOC-20150206727 | JANSSEN | 69.29 | YR | E | M | Y | 58.00000 | KG | 20160729 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
108021295 | 10802129 | 1 | PS | SOVRIAD | SIMEPREVIR | 1 | Oral | N | 205123 | 100 | MG | CAPSULE | QD | ||||||
108021295 | 10802129 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | Y | 0 | 200 | MG | UNSPECIFIED | QD | ||||||
108021295 | 10802129 | 3 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | Y | 0 | 600 | MG | UNSPECIFIED | QD | ||||||
108021295 | 10802129 | 4 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | Y | 0 | 400 | MG | UNSPECIFIED | QD | ||||||
108021295 | 10802129 | 5 | SS | PEGINTRON | PEGINTERFERON ALFA-2B | 1 | Subcutaneous | Y | 0 | 1 | UG/KG | INJECTION | QD | ||||||
108021295 | 10802129 | 6 | SS | PEGINTRON | PEGINTERFERON ALFA-2B | 1 | Subcutaneous | Y | 0 | 1.3 | UG/KG | INJECTION | /wk | ||||||
108021295 | 10802129 | 7 | C | METGLUCO | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 8 | C | THYRADIN-S | LEVOTHYROXINE | 1 | Oral | 0 | 100 | UG | POWDER | QD | |||||||
108021295 | 10802129 | 9 | C | LASIX | FUROSEMIDE | 1 | Oral | 0 | 20 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 10 | C | TAKEPRON | LANSOPRAZOLE | 1 | Oral | 0 | 1 | DF | TABLET | QD | |||||||
108021295 | 10802129 | 11 | C | MIYA-BM | CLOSTRIDIUM BUTYRICUM SPORES STRAIN M-55 | 1 | Oral | 0 | 6 | DF | TABLET | QD | |||||||
108021295 | 10802129 | 12 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 2 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 13 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 3.5 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 14 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 3 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 15 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | .5 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 16 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | .5 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 17 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 1 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 18 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 2.5 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 19 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 2 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 20 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 1 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 21 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 2 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 22 | C | WARFARIN | WARFARIN | 1 | Oral | 0 | 2 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 23 | C | URSO | URSODIOL | 1 | Oral | 0 | 300 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 24 | C | LEVOCARNITINE HYDROCHLORIDE | LEVOCARNITINE HYDROCHLORIDE | 1 | Oral | 0 | 1800 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 25 | C | TEPRENONE | TEPRENONE | 1 | Oral | 0 | 150 | MG | CAPSULE | QD | |||||||
108021295 | 10802129 | 26 | C | FLUVASTATIN SODIUM. | FLUVASTATIN SODIUM | 1 | Oral | 0 | 20 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 27 | C | LOXOPROFEN | LOXOPROFEN | 1 | Oral | 0 | 60 | MG | UNSPECIFIED | QD | |||||||
108021295 | 10802129 | 28 | C | REBAMIPIDE | REBAMIPIDE | 1 | Oral | 0 | 100 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 29 | C | FEBURIC | FEBUXOSTAT | 1 | Oral | 0 | 10 | MG | TABLET | QD | |||||||
108021295 | 10802129 | 30 | C | TRAZENTA | LINAGLIPTIN | 1 | Oral | 0 | 5 | MG | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
108021295 | 10802129 | 1 | Chronic hepatitis C |
108021295 | 10802129 | 2 | Chronic hepatitis C |
108021295 | 10802129 | 3 | Chronic hepatitis C |
108021295 | 10802129 | 4 | Chronic hepatitis C |
108021295 | 10802129 | 5 | Chronic hepatitis C |
108021295 | 10802129 | 6 | Chronic hepatitis C |
108021295 | 10802129 | 7 | Diabetic nephropathy |
108021295 | 10802129 | 8 | Hypothyroidism |
108021295 | 10802129 | 9 | Hypertension |
108021295 | 10802129 | 10 | Prophylaxis |
108021295 | 10802129 | 11 | Prophylaxis |
108021295 | 10802129 | 12 | Prothrombin level abnormal |
108021295 | 10802129 | 13 | Prothrombin level abnormal |
108021295 | 10802129 | 14 | Prothrombin level abnormal |
108021295 | 10802129 | 15 | Prothrombin level abnormal |
108021295 | 10802129 | 16 | Prothrombin level abnormal |
108021295 | 10802129 | 17 | Prothrombin level abnormal |
108021295 | 10802129 | 18 | Prothrombin level abnormal |
108021295 | 10802129 | 19 | Prothrombin level abnormal |
108021295 | 10802129 | 20 | Prothrombin level abnormal |
108021295 | 10802129 | 21 | Prothrombin level abnormal |
108021295 | 10802129 | 22 | Prothrombin level abnormal |
108021295 | 10802129 | 23 | Chronic hepatitis C |
108021295 | 10802129 | 24 | Prophylaxis |
108021295 | 10802129 | 25 | Prophylaxis |
108021295 | 10802129 | 26 | Prophylaxis |
108021295 | 10802129 | 27 | Prophylaxis |
108021295 | 10802129 | 28 | Prophylaxis |
108021295 | 10802129 | 29 | Blood uric acid |
108021295 | 10802129 | 30 | Diabetic nephropathy |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
108021295 | 10802129 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
108021295 | 10802129 | Anaemia | |
108021295 | 10802129 | Blood glucose increased | |
108021295 | 10802129 | Blood uric acid increased | |
108021295 | 10802129 | Brain natriuretic peptide increased | |
108021295 | 10802129 | Glycosylated haemoglobin increased | |
108021295 | 10802129 | Platelet count decreased | |
108021295 | 10802129 | Prothrombin level abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
108021295 | 10802129 | 1 | 20140709 | 20140930 | 0 | |
108021295 | 10802129 | 2 | 20141001 | 20141007 | 0 | |
108021295 | 10802129 | 3 | 20140709 | 20140902 | 0 | |
108021295 | 10802129 | 4 | 20140903 | 20140930 | 0 | |
108021295 | 10802129 | 5 | 20140716 | 20141224 | 0 | |
108021295 | 10802129 | 6 | 20140709 | 20140709 | 0 | |
108021295 | 10802129 | 12 | 20141212 | 0 | ||
108021295 | 10802129 | 13 | 20140805 | 0 | ||
108021295 | 10802129 | 14 | 20140806 | 20140807 | 0 | |
108021295 | 10802129 | 15 | 20141203 | 20141211 | 0 | |
108021295 | 10802129 | 16 | 20141008 | 20141113 | 0 | |
108021295 | 10802129 | 17 | 20141203 | 20141211 | 0 | |
108021295 | 10802129 | 18 | 20140808 | 20140918 | 0 | |
108021295 | 10802129 | 19 | 20140919 | 20140930 | 0 | |
108021295 | 10802129 | 20 | 20141002 | 20141007 | 0 | |
108021295 | 10802129 | 21 | 20141008 | 20141113 | 0 | |
108021295 | 10802129 | 22 | 20141114 | 20141202 | 0 | |
108021295 | 10802129 | 24 | 20140709 | 20141231 | 0 | |
108021295 | 10802129 | 25 | 20140709 | 20141231 | 0 | |
108021295 | 10802129 | 26 | 20140709 | 20141231 | 0 | |
108021295 | 10802129 | 27 | 20140709 | 20140709 | 0 | |
108021295 | 10802129 | 28 | 20140709 | 20140709 | 0 | |
108021295 | 10802129 | 29 | 20140806 | 20141231 | 0 |